Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ResMed

Global demand helps push ResMed shares to record high

ResMed shares have hit an all-time high after the medical device-maker beat expectations on both revenue and profit.

Stocks To Watch: ResMed Sees RS Rating Jump To 82

Stocks To Watch: ResMed Sees RS Rating Jump To 82

ResMed sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Are Wall Street Analysts Bullish on ResMed Stock?

Are Wall Street Analysts Bullish on ResMed Stock?

Although ResMed has outperformed the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

ResMed Hits 80-Plus Relative Strength Rating Benchmark

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Investors Business Daily

ResMed Earns IBD Stock Rating Upgrade

On Monday, ResMed got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

Investors Business Daily

ResMed Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

ResMed Sees RS Rating Improve To 77

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Solid earnings and tariff break awaken ResMed price

Solid earnings and tariff break awaken ResMed price

While US President Donald Trump's tariffs have sent global markets into a tailspin, medical technology companies are well-positioned to weather the storm.

Earnings Preview: What to Expect From ResMed’s Report

Earnings Preview: What to Expect From ResMed’s Report

ResMed is set to release its fiscal third-quarter earnings this month, with analysts forecasting a lower-double-digit growth in profits.

ResMed Shows Improved Relative Price Performance; Still Shy Of Benchmark

ResMed Shows Improved Relative Price Performance; Still Shy Of Benchmark

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investors Business Daily

Stocks With Rising Relative Strength: ResMed

Stocks With Rising Relative Strength: ResMed

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Is ResMed Stock Outperforming the Dow?

Is ResMed Stock Outperforming the Dow?

Despite ResMed’s outperformance relative to the Dow Jones over the past year, analysts are cautiously optimistic about the stock’s prospects.

ResMed Shows Market Leadership With Jump To 81 RS Rating

ResMed Shows Market Leadership With Jump To 81 RS Rating

ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 74 to 81.

Investors Business Daily

ResMed Among Top Stocks For Recent And Long-Term Profit Growth

ResMed Among Top Stocks For Recent And Long-Term Profit Growth

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The global sleep crisis is costing companies. These 3 things are driving it.

Globally, 71% of employed respondents have called in sick due to poor sleep at least once in their career.

Investors Business Daily

Stocks With Rising Relative Strength: ResMed

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investors Business Daily

ResMed Close To Joining Very Elite Stock Group

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Dow Jones Futures Rise; S&P 500 Nears High As Apple Triggers Buy Signal

The Dow and S&P 500 are near all-time highs early Friday as Apple stock flashes a buy signal. Deckers and Atlassian diverged on earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

Investors Business Daily

ResMed Receives IBD Stock Rating Upgrade

On Wednesday, ResMed got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

ResMed's Quarterly Earnings Preview: What You Need to Know

ResMed is expected to release its fiscal second-quarter earnings this month, and analysts project a double-digit profit growth.

Investors Business Daily

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Is ResMed Stock Outperforming the Nasdaq?

ResMed has outpaced the broader Nasdaq Composite index over the past year, and Wall Street analysts are moderately bullish about the stock’s prospects.

ResMed Stock: Is Wall Street Bullish or Bearish?

Although ResMed has outperformed relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Fabric face mask to help apnoea sufferers rest easy

After double-digital sales growth last quarter, ASX-listed medical device maker ResMed has launched a product its CEO had been dreaming about for a decade.

People

129,965 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

Investor Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

290,216 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play